Solid-phase extraction for the high-performance liquid chromatographic determination of indomethacin, suxibuzone, phenylbutazone and oxyphenbutazone in plasma, avoiding degradation of compounds

Caturla, Maria Cruz; Cusido, E.

doi:10.1016/0378-4347(92)80452-v

Cited by 21 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Important issue during NSAIDs analysis is tendency to degradation of some NSAIDs. Especially PBZ, OPB are susceptible to oxidation during analysis [20]. Usefulness of use of ascorbic acid as an anti-oxidant agent during solid phase extraction clean-up was reported by Gowik et al [21] and confirmed also in our study [22].…”

Section: Sample Preparationsupporting

confidence: 75%

Determination of non-steroidal anti-inflammatory drugs residues in animal muscles by liquid chromatography–tandem mass spectrometry

Jedziniak

Szprengier-Juszkiewicz

Olejnik

et al. 2010

Analytica Chimica Acta

View full text Add to dashboard Cite

Section: Sample Preparationsupporting

confidence: 75%

Determination of non-steroidal anti-inflammatory drugs residues in animal muscles by liquid chromatography–tandem mass spectrometry

Jedziniak

Szprengier-Juszkiewicz

Olejnik

et al. 2010

Analytica Chimica Acta

View full text Add to dashboard Cite

“…The concentrations of SBZ and its metabolites in plasma and synovial fluid were measured by an HPLC method based on a modification of a previously published method (Caturla and Cusido 1992). Indomethacin was added as internal standard to plasma and synovial samples.…”

Section: Determination Of Plasma and Synovial Fluid Concentrations Ofmentioning

confidence: 99%

Disposition and tolerance of suxibuzone in horses

Jaraiz

Rodríguez

Andrés

et al. 1999

Equine Veterinary Journal

View full text Add to dashboard Cite

Summary Suxibuzone (SBZ), a nonsteroidal anti‐inflammatory drug, was administered to 6 horses at a dose rate of 7.5 mg/kg bwt by intravenous (i.v.) route. Plasma and synovial fluid concentrations of suxibuzone and its main active metabolites, phenylbutazone (PBZ) and oxyphenbutazone (OPBZ), were measured simultaneously by a sensitive and specific high‐performance liquid chromatographic method. The pharmacokinetic parameters were determined by noncompartmental analysis. Plasma SBZ concentrations rapidly decreased and were not detectable beyond 20 min after treatment. The parent drug was not detected in any synovial fluid samples. Average maximum plasma concentrations of PBZ (16.43 μg/ml) and OPBZ (2.37 μg/ml) were attained at 0.76 and 7.17 h, respectively. The mean residence time (MRT) of PBZ was 6.96 h in plasma. Oxyphenbutazone plasma concentrations were below those reached by phenylbutazone during the first 12 h after suxibuzone administration, even though its values were detectable for at least 24 h (MRT = 10.65 h). Plasma concentrations of PBZ and OPBZ exceeding EC50 and IC50 of TXB2 and PGE2 were reached by at least 12 h. Synovial fluid concentrations of PBZ and OPBZ were 2.87 ± 0.37 μg/ml and 0.97 ± 0.08 ug/ml at 9 h after suxibuzone administration and exceeded IC50 of PGE2 for at least this time. In the present study, suxibuzone was well tolerated following i.v. injection.

show abstract

“…The concentrations of SBZ and its metabolites in plasma and synovial fluid were measured by a high performance liquid chromatography (HPLC) method based on a modification of a previously published method ( Caturla & Cusido, 1992). Indomethacin was added to all plasma and synovial fluid samples as an internal standard.…”

Section: Methodsmentioning

confidence: 99%

Pharmacokinetics and bioequivalence of two suxibuzone oral dosage forms in horses

Jaraiz

Rodríguez

Andrés

et al. 1999

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

A disposition and bioequivalence study with a suxibuzone granulated and a suxibuzone paste oral formulation was performed in horses. Suxibuzone (SBZ) is a nonsteroidal anti-inflammatory drug, which was administered to horses (n = 6) at a dosage of 19 mg/kg bwt by the oral route (p.o.) in a two period cross-over design. Suxibuzone is very rapidly transformed into its main active metabolites, phenylbutazone (PBZ) and oxyphenbutazone (OPBZ). Therefore plasma and synovial fluid concentrations of SBZ, PBZ and OPBZ were simultaneously measured by a sensitive and specific high-performance liquid chromatographic method. The pharmacokinetic parameters were determined by noncompartmental analysis. Suxibuzone could not be detected in any plasma and synovial fluid samples (< 0.04 microgram/mL). Plasma PBZ and OPBZ concentrations were detected between 30 min and 72 h after granulate and paste administration. Mean plasma concentration of PBZ peaked at 5 h (34.5 +/- 6.7 micrograms/mL) and at 7 h (38.8 +/- 8.4 micrograms/mL), and mean area under the concentration-time curve (AUC0-->LOQ) was 608.0 +/- 162.2 micrograms.h/mL and 656.6 +/- 149.7 micrograms.h/mL after granulate and paste administration, respectively. Mean plasma concentration of OPBZ increased to 5-6.7 micrograms/mL, with the maximum concentration (Cmax) appearing between 9 and 12 h after administration of both formulations. The AUCs0-->LOQ for OPBZ were also similar (141.8 +/- 48.3 micrograms.h/mL granulate vs. 171.4 +/- 45.0 micrograms.h/mL paste). It was concluded that the suxibuzone products were bioequivalent with respect to PBZ. For OPBZ, the 95% confidence intervals of the pharmacokinetic parameters were within the acceptable range of 80-125%. The paste formulation provided greater bioavailability of PBZ and OPBZ.

show abstract

Solid-phase extraction for the high-performance liquid chromatographic determination of indomethacin, suxibuzone, phenylbutazone and oxyphenbutazone in plasma, avoiding degradation of compounds

Cited by 21 publications

References 14 publications

Determination of non-steroidal anti-inflammatory drugs residues in animal muscles by liquid chromatography–tandem mass spectrometry

Determination of non-steroidal anti-inflammatory drugs residues in animal muscles by liquid chromatography–tandem mass spectrometry

Disposition and tolerance of suxibuzone in horses

Pharmacokinetics and bioequivalence of two suxibuzone oral dosage forms in horses

Contact Info

Product

Resources

About